Text Size
1 study found for:    NCT01074970

Modify this search | How to Use Search Results

Show Display Options
Rank Status Study
1 Recruiting PARP Inhibition for Triple Negative Breast Cancer (ER-/PR-/HER2-)With BRCA1/2 Mutations
Condition: Breast Cancer
Interventions: Drug: Cisplatin;   Drug: Rucaparib
To Top

† Indicates status has not been verified in more than two years